GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dermata Therapeutics DRMA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.77

+0.79%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Dermata Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Dermata Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DRMA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $7.6m. At that date it held total assets of $7.9m and shareholders' equity of $6.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Aug 2021
Employees
8
Head office
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Gerald ProehlChairman of the Board, President, Chief Executive Officer, since 2014$461,973
  • Ms. Kyri Van HooseChief Financial Officer, Senior Vice President$464,616
  • Dr. Maria Bedoya Toro MuneraSenior Vice President - Regulatory Affairs & Quality Assurance
  • Dr. Christopher NardoSenior Vice President, Chief Development Officer$492,680
  • Mr. David HaleLead Independent Director$77,986
  • Ms. Brittany BradrickIndependent Director$52,486
  • Ms. Mary FisherIndependent Director$52,486
  • Dr. Steven MentoIndependent Director$48,986
  • Dr. Andrew SandlerIndependent Director$53,986
  • Ms. Kathleen ScottIndependent Director$59,986
  • Dr. Wendell WierengaIndependent Director$54,986
  • Mr. Cliff MastricolaInvestor Relations, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Dermata Therapeutics focuses on innovative Spongilla technology for skin disease treatments.
  • DMT310 completed Phase Ib proof of concept trial in psoriasis.
  • DMT410 combines sponge powder with botulinum toxin for dermal delivery.

Weaknesses

  • The company has only 8 full-time employees.
  • Dermata Therapeutics went public on 13 August 2021.
  • Dermata Therapeutics is a clinical-stage company with limited commercial experience.

Opportunities

  • DMT310 targets acne vulgaris as its initial focus.
  • DMT410 aims for aesthetic skin treatments with combination therapy.
  • The US market offers significant potential for dermatology pharmaceuticals.

Threats

  • Dermata Therapeutics faces competition in the US dermatology sector.
  • The company's clinical-stage status poses development risks.
  • Regulatory approval delays could impact product timelines.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.